Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Geron Aims For Fall Return To The Clinic

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Geron was the first stem cell therapy company to the clinic, with a plan to inject OPC1, made of embryonic glial progenitor cells, into the spinal cords of paralyzed patients. The idea is that once injected at the site of the nerve damage, the oligodendrocytes go to work rebuilding the insulating myelin sheath around the nerves and produce nerve growth factors called neutrophins that stimulate regrowth of nerve tissue.

You may also be interested in...

Geron Gets Green Light To Test Embryonic Stem Cell Therapy On Humans

After being delayed since May, Geron’s 21,000-page application clears overnight in the first week of the Obama administration.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts